Saved in:
Bibliographic Details
Main Authors: Gilbert, Peter B., Peng, James, Han, Larry, Lange, Theis, Lu, Yun, Nie, Lei, Shih, Mei-Chiung, Waddy, Salina P., Wiley, Ken, Yann, Margot, Zafari, Zafar, Ghosh, Debashis, Follmann, Dean, Juraska, Michal, Díaz, Iván
Format: Preprint
Published: 2024
Subjects:
Online Access:https://arxiv.org/abs/2407.06350
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1866914862693613568
author Gilbert, Peter B.
Peng, James
Han, Larry
Lange, Theis
Lu, Yun
Nie, Lei
Shih, Mei-Chiung
Waddy, Salina P.
Wiley, Ken
Yann, Margot
Zafari, Zafar
Ghosh, Debashis
Follmann, Dean
Juraska, Michal
Díaz, Iván
author_facet Gilbert, Peter B.
Peng, James
Han, Larry
Lange, Theis
Lu, Yun
Nie, Lei
Shih, Mei-Chiung
Waddy, Salina P.
Wiley, Ken
Yann, Margot
Zafari, Zafar
Ghosh, Debashis
Follmann, Dean
Juraska, Michal
Díaz, Iván
contents For many rare diseases with no approved preventive interventions, promising interventions exist, yet it has been difficult to conduct a pivotal phase 3 trial that could provide direct evidence demonstrating a beneficial effect on the target disease outcome. When a promising putative surrogate endpoint(s) for the target outcome is available, surrogate-based provisional approval of an intervention may be pursued. We apply the Causal Roadmap rubric to define a surrogate endpoint based provisional approval causal roadmap, which combines observational study data that estimates the relationship between the putative surrogate and the target outcome, with a phase 3 surrogate endpoint study that collects the same data but is very under-powered to assess the treatment effect (TE) on the target outcome. The objective is conservative estimation/inference for the TE with an estimated lower uncertainty bound that allows (through two bias functions) for an imperfect surrogate and imperfect transport of the conditional target outcome risk in the untreated between the observational and phase 3 studies. Two estimators of TE (plug-in, nonparametric efficient one-step) with corresponding inference procedures are developed. Finite-sample performance of the plug-in estimator is evaluated in two simulation studies, with R code provided. The roadmap is illustrated with contemporary Group B Streptococcus vaccine development.
format Preprint
id arxiv_https___arxiv_org_abs_2407_06350
institution arXiv
publishDate 2024
record_format arxiv
spellingShingle A Surrogate Endpoint Based Provisional Approval Causal Roadmap
Gilbert, Peter B.
Peng, James
Han, Larry
Lange, Theis
Lu, Yun
Nie, Lei
Shih, Mei-Chiung
Waddy, Salina P.
Wiley, Ken
Yann, Margot
Zafari, Zafar
Ghosh, Debashis
Follmann, Dean
Juraska, Michal
Díaz, Iván
Methodology
For many rare diseases with no approved preventive interventions, promising interventions exist, yet it has been difficult to conduct a pivotal phase 3 trial that could provide direct evidence demonstrating a beneficial effect on the target disease outcome. When a promising putative surrogate endpoint(s) for the target outcome is available, surrogate-based provisional approval of an intervention may be pursued. We apply the Causal Roadmap rubric to define a surrogate endpoint based provisional approval causal roadmap, which combines observational study data that estimates the relationship between the putative surrogate and the target outcome, with a phase 3 surrogate endpoint study that collects the same data but is very under-powered to assess the treatment effect (TE) on the target outcome. The objective is conservative estimation/inference for the TE with an estimated lower uncertainty bound that allows (through two bias functions) for an imperfect surrogate and imperfect transport of the conditional target outcome risk in the untreated between the observational and phase 3 studies. Two estimators of TE (plug-in, nonparametric efficient one-step) with corresponding inference procedures are developed. Finite-sample performance of the plug-in estimator is evaluated in two simulation studies, with R code provided. The roadmap is illustrated with contemporary Group B Streptococcus vaccine development.
title A Surrogate Endpoint Based Provisional Approval Causal Roadmap
topic Methodology
url https://arxiv.org/abs/2407.06350